Novartis Ag

Corcept Therapeutics Incorporated

Peter Hunt

Catherine Howsham

Lee Edwards

Nichola Smith

Gurdip Bhalay

Urs Baettig

Stephen Paul Collingwood

Simon James Watson

Neil John Press

Thomas Anthony Hunt

Anne-Marie D'Souza

Emma Budd

Paul Joseph Oakley

Graham Charles Bloomfield

Andrew Dunstan

Peter Gedeck

Nikolaus Johannes Stiefl

Catherine LeBlanc

Robert Alexander Pulz

Hazel Joan Hunt

Lorna Duffy

Katrin Spiegel

Mark Mills

Andrew William Phillips

Claire Adcock

Nicholas James Devereux

Thomas Hornsby

Morgan Jouanneau

Maude Nadine Pierrette Pipet

Andrew James Smith

Paul Oakley

Catherine Leblanc

Anne-Marie D'souza

The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Bicyclic indazole glucocorticoid receptor antagonists

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, R, R, R, R, and Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrazine derivatives as ENaC blockers

The present invention relates to compounds of formula (I) wherein X, R, R, R, Rand Rare as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Squaramide derivatives as CXCR2 antagonist

Compounds of formula (I) in free or salt or solvate form, where T, T, and Thave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. 

Organic compounds

Pyrazine derivatives as enac blockers

Compounds of formula I in free or salt or solvate form, where T, T, X, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

A compound of Formula I or a hydrate or solvate thereof, where R, R, R, R, R, R, R, R, R, and Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrazine derivatives as ENAC blockers

Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel

Growing community of inventors

Horsham, United Kingdom

Peter Hunt